Respiratory syncytial virus (RSV) is the most common cause of viral lower respiratory tract infections in infants and children under the age of 5. Studies examining RSV infection in susceptible BALB/c mice indicate that both CD4 and CD8 T cells not only contribute to viral clearance but also facilitate RSV-induced disease. However, efforts to understand the mechanisms by which RSV-specific T cells mediate disease following acute RSV infection have been hampered by the lack of defined RSV-specific T cell epitopes. Using an overlapping peptide library spanning each of the RSV-derived proteins, intracellular cytokine staining for gamma interferon was utilized to identify novel RSV-specific CD4 and CD8 T cell epitopes. Five novel CD8 T cell epitopes were revealed within the RSV fusion (F) protein and glycoprotein (G). In addition, five previously unidentified CD4 T cell epitopes were discovered, including epitopes in the phosphoprotein (P), polymerase protein (L), M2-1 protein, and nucleoprotein (N). Though the initial CD4 T cell epitopes were 15 amino acids in length, synthesis of longer peptides increased the frequency of responding CD4 T cells. Our results indicate that CD4 T cell epitopes that are 17 amino acids in length result in more optimal CD4 T cell stimulation than the commonly used 15-mer peptides.
R
espiratory syncytial virus (RSV), a single-stranded negativesense RNA paramyxovirus, is the leading cause of hospitalizations for lower respiratory tract infections in young children (1) . RSV is a ubiquitous pathogen, infecting 30 to 60% of children during their first year of life and up to 90% of children by their second year of life (2) (3) (4) . Furthermore, approximately 3% of RSVinfected children require hospitalization (5) . In total, it is estimated that worldwide, RSV is responsible for 3.4 million acute lower respiratory tract infections annually in children under the age of 5, resulting in up to 196,000 yearly fatalities (6) . In addition to children, the elderly are also susceptible to severe RSV-induced disease (7) .
BALB/c mice are susceptible to RSV infection and have been used extensively to examine the role of the immune response in mediating viral clearance and contributing to the development of immunopathology following infection. Studies in BALB/c mice have demonstrated that although both CD4 and CD8 T cells mediate viral clearance, CD4 and CD8 T cells also contribute to RSVassociated disease (8) . Furthermore, several human studies have demonstrated that the increased presence of T cells is correlated to severe RSV disease in both children and the elderly (9) (10) (11) (12) .
The breadth of the CD4 and CD8 T cell responses against RSV has not been thoroughly explored. Utilizing a recombinant vaccinia virus (VacV)-based vaccination system to boost the T cell response against the RSV-derived glycoprotein (G) and fusion protein (F), two RSV-derived CD4 epitopes, G [183] [184] [185] [186] [187] [188] [189] [190] [191] [192] [193] [194] [195] and F 51-66, have been previously identified (13) (14) (15) (16) . However, upon acute RSV infection, both epitopes represent only a small fraction (i.e., 1 to 2%) of lung CD4 T cells (17) . Furthermore, several RSV-specific CD8 T cell epitopes have been described. Identified epitopes include the immunodominant epitope M2-1 [82] [83] [84] [85] [86] [87] [88] [89] [90] (18) (19) (20) and the subdominant epitopes M2-1 [127] [128] [129] [130] [131] [132] [133] [134] [135] (21) and F [85] [86] [87] [88] [89] [90] [91] [92] [93] (22) . Much like the previously identified CD4 T cell epitopes, these epitopes were defined utilizing a recombinant VacV immunization system (18) (19) (20) 22) or upon secondary RSV challenge (21) . Furthermore, these studies utilized peptide libraries that span only the individual RSV M2-1 and F proteins (19, 21, 22) . Therefore, the other 9 RSV-derived proteins have not been thoroughly examined for potential CD8 T cell epitopes.
In this study, we utilized a peptide library spanning the entire RSV proteome to identify novel CD4 and CD8 T cell epitopes. We identified 5 novel CD4 T cell epitopes and 5 novel CD8 T cell epitopes directed against RSV. Furthermore, we found that the previously identified RSV-Long CD8 T cell epitope F 249 -258 (23) also serves as a CD8 T cell epitope against RSV-A2. Additionally, we have demonstrated that the addition of amino acids to the commonly used 15-mer CD4 T cell epitopes to form 17-mer epitopes results in a substantial increase in the immunogenicity of the epitope.
MATERIALS AND METHODS
Mice and viruses. BALB/cAnNCr mice between 6 and 8 weeks of age were purchased from the National Cancer Institute (Frederick, MD). Female mice were used in all experiments. The A2 strain of RSV (RSV-A2) was a gift from Barney S. Graham (National Institutes of Health, Bethesda, MD) and was propagated on HEp-2 cells (American Type Culture Collection [ATCC], Manassas, VA) (24) . Mice were infected intranasally (i.n.) with 2 ϫ 10 6 to 3 ϫ 10 6 PFU RSV-A2 (25) . Recombinant VacV expressing the RSV-derived F protein (VacV-F) was a gift from Thomas J. Braciale (University of Virginia, Charlottesville, VA) and J. L. Beeler (U.S. Food and Drug Administration, Bethesda, MD) and was propagated in BSC-40 cells (ATCC). Mice were scarified with 3 ϫ 10 6 PFU of recombinant VacV-F (26). All experimental procedures utilizing mice were approved by the University of Iowa Animal Care and Use Committee.
Intracellular cytokine stain. Spleen cells from day 8 RSV-infected mice were harvested and single-cell suspensions were generated as previously described (27) . Splenocytes (1.5 ϫ 10 6 ) were incubated with 1 M peptide from an overlapping peptide library (15-mers overlapping every 10 amino acids), spanning the entirety of the RSV-A2-proteome (Mimotopes Pty. Ltd., Roseville, MN) in the presence of 10 g/ml brefeldin A (BFA) (Sigma-Aldrich, St. Louis, MO) for 5 h at 37°C (24) . Following stimulation, cells were surface stained with antibodies specific to CD4, CD8, and CD90.2 (Biolegend, San Diego, CA) as previously described (24) . Intracellular cytokine staining (ICS) for gamma interferon (IFN-␥) (Biolegend) was performed, and cells were analyzed on a BD FACSCanto instrument (BD Bioscience, San Jose, CA). Data were analyzed using the FlowJo software program (Tree Star, Ashland, OR). Candidate epitopes were identified as having results Ն2 standard deviations (SD) over those for the no-peptide controls in at least one of two experiments.
For analysis of lung mononuclear cells, lungs were harvested from day 8 RSV-infected mice, and single-cell suspensions were generated as previously described (27) . Cells (1.5 ϫ 10 6 ) were incubated with 1 M peptide (Mimotopes) identified in the initial screening experiments or synthesized peptides (Biosynthesis, Lewisville, TX) in the presence of 10 g/ml BFA for 5 h at 37°C. Following stimulation, cells were surface stained with antibodies specific to CD4, CD8, and CD90.2 and stained intracellularly for IFN-␥ (24). For CD107␣ staining, cells were incubated in the presence of 10 g/ml monensin alone or stimulated with the newly identified peptides and CD107␣ antibody (BD Bioscience). All antibodies were purchased from BioLegend unless otherwise stated. Stained cells were analyzed on either a BD FACSCanto or BD LSRFortessa instrument (BD Bioscience). Data were evaluated using FlowJo software. Confirmed epitopes were identified as having results Ն2 SD over those for the nopeptide controls in at least two of three experiments or Ն1 SD in all three experiments. In some experiments, the fold increase of IFN-␥ ϩ CD4 T cells stimulated by 17-mer peptides versus results with their respective 15-mer peptide was determined by the following calculation: (% of cells responding to 17-mer peptides Ϫ % of cells for BFA control)/(% of cells responding to 15-mer peptides Ϫ % of cells for BFA control).
Splenic dendritic cell isolation and dendritic cell immunization. BALB/c mice were given an intraperitoneal injection with 5 ϫ 10 6 B16 cells expressing Fms-related tyrosine kinase 3 ligand (kindly provided by Martin Prlic and Michael J. Bevan). Fourteen to seventeen days following injection, mice were administered 2 g of lipopolysaccharide (LPS) intravenously to mature the dendritic cells (DCs), and spleens were harvested 16 h later. Spleens were digested with DNase and collagenase for 20 min at 37°C with shaking (100 rpm), and mononuclear cells were isolated by pressing the tissue through a wire mesh screen (Cellector; Bellco Glass, Inc., Vineland, NJ). Red blood cells were lysed with NH 4 Cl and washed, and cells were stained with CD11c-phycoerythrin (PE) (Biolegend). Cells were incubated with anti-PE microbeads (Miltenyi Biotec, Auburn, CA), and splenic DCs were isolated by positive selection using an AutoMACS instrument. Following isolation, splenic DCs were resuspended in 2 parts supplemented RPMI 1640 to 1 part B16-Flt3L-conditioned medium plus recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) (1,000 U/ml) and incubated with 2 M G 271-285 peptide for 2 h at 37°C with shaking (100 rpm). Following peptide pulse, splenic DCs were washed and resuspended in saline, and 5 ϫ 10 5 peptide-pulsed splenic DCs were subsequently injected intravenously into naive BALB/c mice.
MHC class I restriction assay. Mice were immunized with 3 ϫ 10 6 PFU VacV-F by scarification at the base of the tail (26) . Twenty-one days following immunization, mice were infected with RSV. Six days following RSV infection, lungs were harvested and single-cell suspensions were generated as described above. Cells were stimulated at a 1:1 effector-to-stimulator (E:S) ratio with peptide-pulsed parent L929 cells or
3.3; kindly provided by Ted H. Hansen, Washington University, St. Louis, MO) for 5 h at 37°C. Following stimulation, cells were surface stained with monoclonal antibodies (MAbs) specific to CD4, CD8, and CD90.2. ICS for IFN-␥ (Biolegend) was performed, and cells were analyzed using a BD LSRFortessa instrument (24) . Data were evaluated using FlowJo software.
In some experiments, DC-primed mice (described above) were infected with RSV 8 days following immunization with splenic DC plus G 271-285 . Five days following RSV infection, lungs were harvested and lung single-cell suspensions were generated as described above. Cells were stimulated with peptide-pulsed cell lines as described above. Following stimulation, cells were surface stained with MAbs specific to CD4, CD8, and CD90.2. ICS for IFN-␥ (Biolegend) was performed, and cells were analyzed using a BD LSRFortessa instrument (24) . Data were evaluated using FlowJo software.
Prediction of major histocompatibility complex class I epitopes. Following confirmation of the major histocompatibility complex (MHC) class I restriction, the MHC class I binding predictions of each library epitope were made using the immune epitope database (IEDB) analysis resource consensus tool (28) , which combines predictions from artificial neural networks (ANN), also known as NetMHC (29, 30) , stabilized matrix method (SMM), (31) and comblib (32) . Utilizing this method, we predicted that the following were the core CD8 T cell epitopes: F 32-40 , F 52-59 , F 163-171 , and F 167-175 . However, the best match predicted for the G 271-285 epitope was a 13-mer peptide. Therefore, this epitope was not synthesized. The consensus core epitopes were synthesized (Biosynthesis) and utilized to stimulate lung CD8 T cells from day 8 RSV-infected mice as described previously (24) . Following stimulation, cells were surface stained for CD8 and CD90.2, and an ICS for IFN-␥ was performed. Stained cells were subsequently analyzed on a BD LSRFortessa instrument, and data were evaluated using FlowJo software (24) .
RESULTS

Identification of candidate CD4 and CD8 T cell epitopes against RSV-A2.
A set of 889 15-mer peptides, overlapping every 10 amino acids, spanning the entire RSV-A2 proteome was generated. To identify candidate RSV-derived CD4 and CD8 T cell epitopes, splenocytes isolated from day 8 RSV-infected BALB/c mice were stimulated with individual peptides from the RSV peptide library. Reactivity was determined by ICS for IFN-␥, and candidate CD4 and CD8 T cell epitopes were identified as having results Ն2 SD above those for the no-peptide controls (0.18% and 0.26%, respectively).
To confirm the efficacy of the experimental design, we determined if the previously identified immunodominant CD4 T cell epitope G [183] [184] [185] [186] [187] [188] [189] [190] [191] [192] [193] [194] [195] and its respective peptide within the peptide library, G [181] [182] [183] [184] [185] [186] [187] [188] [189] [190] [191] [192] [193] [194] [195] , met the Ն2-SD threshold (Fig. 1A) . Similarly, we determined if the CD8 T cell immunodominant epitope M2-1 82-90 and the subdominant epitope F 85-93 and their respective peptides within the peptide library (M2-1 81-90 and F 81-95 ) also met the Ն2-SD threshold ( Fig. 2A) . The G [183] [184] [185] [186] [187] [188] [189] [190] [191] [192] [193] [194] [195] and M2-1 82-90 CD4 and CD8 T cell epitopes, respectively, and their respective epitopes within the peptide library all stimulated responses that exceeded the 2-SD threshold (Fig. 1A and 2A, respectively) . Furthermore, although the optimal F 85-93 subdominant CD8 T cell epitope elicited a response slightly under the 2-SD threshold, the library peptide containing this epitope (F 81-95 ) stimulated a response that exceeded the 2-SD threshold. Overall, these data indicate that this approach is sufficient to detect RSV-derived CD4 and CD8 T cell epitopes. Utilizing this approach, we identified 85 candidate peptides that stimulated IFN-␥ production by splenic CD4 T cells (Fig. 1B) and 141 candidate peptides that stimulated IFN-␥ production by splenic CD8 T cells (Fig. 2B) .
Confirmation of CD4 T cell and CD8 T cell epitopes. To verify the candidate CD4 T cell epitopes, lung mononuclear cells were isolated from RSV-infected BALB/c mice and were stimulated with the candidate peptides identified in the initial screen (Fig.  1B) . A total of 6 peptides, including the peptide containing the previously described G [183] [184] [185] [186] [187] [188] [189] [190] [191] [192] [193] [194] [195] epitope, stimulated IFN-␥ production by CD4 T cells (Fig. 3) . RSV-A2 infection, production of interleukin 5 (IL-5), IL-13, and IL-17A by CD4 T cells was evaluated following stimulation with each of the newly identified CD4 peptides. We did not observe a significant population of CD4 T cells that produced any of these cytokines following peptide stimulation (data not shown).
Similarly, CD8 T cell epitopes were verified by stimulating CD8 T cells from day 8 RSV-infected lungs with the candidate peptides identified in Fig. 2B . Four peptides containing novel CD8 T cell epitopes stimulated IFN-␥ production from lung CD8 T cells (Fig.  4) . As expected, the library peptides containing the previously described CD8 T cell epitopes M2-1 82-90 , M2-1 127-135 , and F 85-93 also stimulated IFN-␥ production by CD8 T cells (18) (19) (20) 22) . In addition, the peptide containing the previously identified RSVLong epitope F 249 -258 (F 246 -260 ) stimulated IFN-␥ production by CD8 T cells following RSV-A2 infection (23) . The amino acid sequence in this region is conserved between the two virus strains, indicating that this peptide serves as a CD8 T cell epitope against both RSV-A2 and RSV-Long infection. Compared to that of CD4 T cells, the CD8 T cell specificity against RSV was more restricted, targeting only the M2-1 protein (M2-1 82-90 and M2-1 127-135 (Fig. 5A ). Consistent with previous data, VacV-G immunization failed to prime a CD8 T cell response (37) (38) (39) . Therefore, we utilized a low-inflammation DC immunization protocol to boost the G 271-285 -specific CD8 T cell response (40) . Eight days following immunization with G 271-285 -pulsed DCs, mice were infected with RSV. Lung mononuclear cells were isolated at day 5 postinfection and subsequently stimulated with peptide-pulsed L929 fibroblast cell lines expressing H-2K
d . IFN-␥ production was examined by ICS to determine reactivity. In contrast to the RSV F-derived epitopes, the G 271-285 epitope was H-2L d restricted (Fig.  5B) , thus making G 271-285 the only RSV-derived epitope described to date that is not H-2K d restricted. Confirmation of minimal core CD8 T cell epitopes. Following determination of the MHC class I restriction of the CD8 T cell epitopes, the minimal core epitope sequence was predicted utilizing the IEDB analysis resource (28) . Using this database, we predicted the minimal sequences for the F 26 -40 and F 46 -60 epitopes: F 32-40 and F [52] [53] [54] [55] [56] [57] [58] [59] , respectively. Furthermore, F 161-175 contained two predicted minimal epitopes: F 163-171 and F 167-175 . These core epitopes were synthesized and tested for confirmation. All four minimal core epitopes were confirmed to be stimulatory using ICS (Fig. 6A) . Furthermore, the F 249 -257 minimal core epitope induced IFN-␥ production from CD8 T cells following RSV-A2 infection, demonstrating that this peptide serves as a CD8 T cell epitope against both RSV-A2 and RSV-Long (Fig. 6A) . In addition to IFN-␥ production, CD107␣ expression by CD8 T cells was evaluated following stimulation with all of the newly identified epitopes (Fig. 6B) . Stimulation with all peptides induced CD107␣ expression on CD8 T cells, indicating that these T cells were capable of undergoing degranulation. Considering these confirmed epitopes along with the previously identified M2-1 82-90 , M2-1 127-135 , and F 85-93 epitopes and the identified G 271-285 epitope (Fig. 4) , there are now a total of 8 RSV-derived CD8 T cell epitopes ( Table 1) .
Enhancement of reactivity to CD4 T cell epitopes. Unlike MHC class I molecules, MHC class II molecules have an openended binding cleft allowing for "overhang" residues when peptide is bound (41) (42) (43) (44) (45) (46) . These flanking residues stabilize the peptide binding to the MHC class II molecule and enhance the immunogenicity of the CD4 T cell response (47) (48) (49) (50) . Although several studies have demonstrated that peptide length can drastically alter the immunogenicity of the CD4 T cell against the respective peptide, the optimal length for MHC class II peptides is unclear (49, (51) (52) (53) . We noted that extension of the G [183] [184] [185] [186] [187] [188] [189] [190] [191] [192] [193] [194] [195] epitope by two N-terminal amino acids resulted in an ϳ2-foldincreased frequency of CD4 T cells that respond to this epitope (Fig. 3) . Furthermore, generation of a 17-mer peptide containing four amino acids on each side of the core resulted in a further enhancement (ϳ1.5-fold) of CD4 T cell reactivity toward this epitope (Fig. 7) . To determine if this observation is universal among MHC class II epitopes, we utilized the IEDB database to predict the core sequence of each of the identified epitopes (Table  2) (54, 55) . Of all of the epitopes examined, the P and N epitopes were predicted to bind with the highest affinity to their respective MHC class II molecule. Given that two of the largest CD4 T cell responses were directed against P [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] and N [251] [252] [253] [254] [255] [256] [257] [258] [259] [260] [261] [262] [263] [264] [265] (Fig. 3) , 17-mer peptides containing four amino acids on each side of the predicted core of both peptides were synthesized. These peptides were subsequently used to stimulate lung mononuclear cells isolated from day 8 RSV-infected mice. We compared the abilities of the 17-mer epitopes, P 39 -55 and N 252-268 , to induce IFN-␥ production by CD4 T cells to those of their respective 15-mer library epitopes, P [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] and N 251-265 . We observed that the generation of 17-mer epitopes resulted in a ϳ2-fold increase in the frequency of CD4 T cells responding to the P epitope and an ϳ5-fold increase in the frequency of responding CD4 T cells for the N epitope (Fig.  7) . These data suggest that 17-mer epitopes increase the frequency of responding CD4 T cells compared to that with the more commonly used 15-mer epitopes.
DISCUSSION
Both CD4 and CD8 T cells contribute to RSV-induced disease following primary infection (8) . Although several studies have examined the role of Th1-, Th2-, and more recently Th17-associated cytokines in mediating RSV-induced disease (9, 56, 57) , the ability to identify RSV-specific CD4 T cells producing these cytokines has been hampered by the lack of defined RSV-derived epitopes. In this study, we sought to identify the specificities of both the CD4 and CD8 T cell response against RSV. Overall, we identified 5 novel CD4 T cell epitopes (Table 2 ) and 5 novel CD8 T cell epitopes (Table 1) . We show that the specificity of the CD4 T cell response against RSV is very broad, targeting 6 of the 11 RSV-derived proteins (G, F, L, M2-1, N, and P). However, the specificity of the CD8 T cell response against RSV is much narrower, targeting only 3 of the RSV-derived proteins (M2-1, G, and F). Furthermore, we show that the immunodominance of the CD8 T cell response is very strong, with almost a third of the total CD8 T cells in the lung being specific for M2 [82] [83] [84] [85] [86] [87] [88] [89] [90] . In contrast, the most immunodominant CD4 T cell epitope, G [181] [182] [183] [184] [185] [186] [187] [188] [189] [190] [191] [192] [193] [194] [195] , represents only 2 to 3% of the total CD4 T cells at the peak of the T cell response following RSV infection. Additionally, the CD4 T cell epitopes together account for approximately ϳ10% of the CD4 T cells in the lung following RSV infection, compared to the CD8 T cell response, where the epitopes account for ϳ45% of the total CD8 T cell population in the lung. A similar disparity has been observed for other viral pathogens, including lymphocytic choriomeningitis virus and VacV (58) (59) (60) (61) .
Priming of a large RSV-specific CD4 T cell response using VacV-G is associated with vaccine-enhanced disease upon subsequent RSV infection (15, 16, 38) . In contrast, VacV-G immunization does not induce a CD8 T cell response (37) (38) (39) . It is currently unclear why VacV-G immunization fails to elicit a CD8 T cell response. One potential explanation may be related to the ability of G to be secreted in the strain of VacV-G utilized in these studies. This secretion of G would result in cross-presentation as the major mechanism for MHC class I presentation of G-associated peptides. In contrast to G, the F protein is not secreted and therefore is processed and loaded onto MHC class I molecules via the classical MHC class I presentation pathway. In concordance with this, we found that all of the CD8 T cell epitopes against the F protein were boosted following VacV-F immunization. Two of the newly defined CD4 T cell epitopes reside within the M2-1 protein. However, VacV-M2-1-primed mice do not exhibit a boosted response to either of the M2-1-derived CD4 T cell epitopes (data not shown). Previous studies from our laboratory have shown that priming an M2-1 82-90 -specific memory CD8 T cell response using VacV-M2-1 plus VacV-G inhibits the expansion of G 183-195 -specific memory CD4 T cells upon subsequent RSV infection (26) . These studies together suggest that the immunodominant CD8 T cell epitope M2-1 82-90 is capable of inhibiting the response to multiple CD4 T cell epitopes in a VacV-priming setting (26, 62, 63) . However, it remains to be determined if the CD8 T cell inhibition of the CD4 T cell response occurs during the acute response (i.e., VacV priming) or during the memory recall response (i.e., RSV infection).
Utilizing cell lines expressing H-2D d , H-2K d , or H-2L d , we were able to determine the MHC restriction of the newly identified CD8 T cell epitopes. Although all of the F-derived epitopes were H-2K d restricted, the G 271-285 epitope was H-2L d restricted. To our knowledge, G 271-285 is the only RSV-derived CD8 T cell epitope in BALB/c mice that is not H-2K d restricted. Utilizing the IEDB database, the minimal core epitopes were predicted and subsequently tested and confirmed. In all, 5 novel RSV-A2-derived CD8 T cell epitopes were confirmed (Fig. 6 ). Attempts were made to identify the MHC class II restriction profiles for the identified CD4 T cell epitopes utilizing I-A d and I-E d transfected-fibroblast cell lines to stimulate CD4 T cells. However, the inefficiency of the fibroblast cells lines hindered our ability to accurately determine the MHC class II restriction profiles for the newly identified CD4 T cell epitopes.
Peptides presented by MHC class II molecules commonly contain "overhanging" residues (41-46) that can provide increased stability for the MHC class II peptide complex (47) (48) (49) (50) . Furthermore, these "overhanging" residues can enhance the immunogenicity of the peptide to stimulate CD4 T cells (47, (50) (51) (52) (53) . However, it is unclear what ideal peptide length is required to elicit optimal CD4 T cell responses. Our data demonstrate that the addition of amino acids to the N-terminal end of the G [183] [184] [185] [186] [187] [188] [189] [190] [191] [192] [193] [194] [195] epitope, for G [181] [182] [183] [184] [185] [186] [187] [188] [189] [190] [191] [192] [193] [194] [195] , results in an ϳ2-fold increase in reactivity toward this epitope (Fig. 3) . Furthermore, the addition of two amino acids on the C-terminal end of the G 181-195 epitope, for G [181] [182] [183] [184] [185] [186] [187] [188] [189] [190] [191] [192] [193] [194] [195] [196] [197] , resulted in a further increase in the frequency of CD4 T cells responding to the G epitope (Fig. 7) . This result was not limited to the RSV G epitope, since the addition of two amino acids to the P 39 -55 epitope (P [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] ) resulted in a 2-fold increase in the frequency of responding CD4 T cells (Fig. 7) . Moreover, the addition of two amino acids to the N 251-265 epitope, for N 252-268 , resulted in a more than 5-fold increase in the frequency of responding CD4 T cells following stimulation. Together, these data indicate that 17-mer peptides induce a higher frequency of responding CD4 T cells than the commonly used 15-mer epitopes, highlighting the importance of anchor residues and emphasizing the complexity in how MHC class II peptide length greatly influences the frequency of CD4 T cells that respond to the epitope following stimulation.
